Detect drug induced liver injury (DILI) early in the drug discovery process with PerkinElmer’s Toxicology Fluorescent Imaging Agent Panel.
Drug-induced liver injury (DILI) is the leading reason for termination of drug discovery research projects and is a significant concern in attrition of new drug molecules reaching phase III clinical trials. DILI can manifest in hepatocellular, cholestatic, and steatotic forms differing in the type and pattern of tissue injury, biomarker expression and inflammation in the liver lobules. Our fluorescent imaging probes can allow you to image acute drug-induced biological changes in inflammation, tissue destruction, metabolic changes, and vascular leak (edema) in a manner that predicts the potential for drug toxicity, often prior to overt histological signs.
The availability of probes at 680 nm and 750 nm wavelengths further offer the opportunity for multiplex imaging of appropriate probe combinations to maximize information gained from research animals.
The Toxicology In Vivo Fluorescent Agents Panel includes the following five probes:
NEV10054EX - AngioSense 680 EX (Vascular probe: Leaks into sites of vascular damage or inflammation)
NEV10091 - Transferrin-Vivo 750 (Transferrin receptor targeted probe: Iron metabolism marker in liver)
NEV10168 - MMPSense 750 FAST (Pan-MMP activatable probe: Secreted marker of stellate cells, Kupffer cells, macrophages, and neutrophils)
NEV11053 - Annexin-Vivo 750 (Death/apoptosis probe: Marker on inflammatory cells; metabolic marker on tumor cells)
NEV11079 - RenninSense 680 FAST (Renin activatable probe: Marker of tissue renin-angiotensin system activity)
For research use only. Not for use in diagnostic procedures.